Matt Symes is an investor with Delin Ventures, a biotech VC fund focused on cell therapies and supporting tools or technology, where his role spans both new investments and supporting existing portfolio companies. He also leads finance and strategy for adthera bio, an early-stage cell therapy CDMO founded by Delin Ventures. Previously he was a consultant at BCG where he was part of the healthcare and private equity practices. He is a Chartered Enterprise Risk Actuary and a fellow of the Actuarial Society of South Africa.